Correlation between Hasford Score with Early Molecular Response in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib

• Main Authors: I Dewa Made Widi Hersana, Siprianus Ugroseno Yudho Bintoro, Ami Ashariati Prayoga, Made Putra Sedana
• Format: Article PeerReviewed
• Language: English; English; English
• Published: Oriental Scientific Publishing Company 2019
• Subjects: R Medicine (General); RC Internal medicine
• Online Access: http://repository.unair.ac.id/96194/1/Correlation%20between%20Hasford%20score%20with%20early%20molecular%20response%20in%20patients%20with%20chronic%20myeloid%20leukemia%20in%20chronic%20phase%20treated%20with%20imatinib.pdf; http://repository.unair.ac.id/96194/2/Correlation%20between%20Hasford.pdf; http://repository.unair.ac.id/96194/3/Correlation%20between%20hasford%20score%20with%20early%20molecular%20response%20in%20patients%20with%20chronic%20myeloid%20leukemia%20in%20chronic%20phase%20treated%20with%20imatinib.pdf; http://repository.unair.ac.id/96194/; https://biomedpharmajournal.org/vol12no1/correlation-between-hasford-score-with-early-molecular-response-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-treated-with-imatinib/; https://dx.doi.org/10.13005/bpj/1631
• Institution: Universitas Airlangga

The aim of the study is to to determine correlation Hasford score and early molecular response in chronic phase BCR-ABL-Positive CML patients treated with imatinib. This is an longitudinal observational study in newly diagnosed patients of CML chronic phase BCR-ABL-Positive treated imatinib from Januari 2017 to September 2017. Patients were stratified according to Hasford score at diagnosis. Q-PCR(Quantitative RT-PCR) were used to monitor BCR-ABL transcription levels after 3 months of imatinib treatment. Correlation between Hasford score with early molecular response were analyzed using Koefisien Kontingensi’s correlation test. Results: Thirty five patients were enrolled in this study consist of 13 male and 22 female. After 3 months of imatinib treatment, EMR were 5 patients (83.3%), 11 patients (61.1%) and 2 patients (18.2%) in low, intermediate, and high risk group patients, respectively. Koefisien kontigensi test showed that there was significant correlation between Hasford score and EMR (p=0.018; r=0.431). The Hasford score correlated to early molecular response in chronic phase BCR-ABL-positive CML patients received imatinib.